Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 19, 2010

View Archived Issues

Clinical development of ChimeriVax-Dengue vaccine updated

EVX-001650 displays antipsychotic activity in mouse models related to schizophrenia

AC-430 confers protection in models of autoimmune and inflammatory conditions

Proof-of-concept secukinumab trial in ankylosing spondylitis meets primary endpoint

Exelixis divulges novel mTORC1 inhibitors

Aveo Pharma advances phase Ib tivozanib/capecitabine combination trial

Orban Biotech receives Qualifying Therapeutic Discovery grant for IBC-VS01 vaccine

Salvat licenses tarafenacin to Kwang Dong Pharma for OAB in South Korea

Morphotek and Hokkaido University join to evaluate amatuximab for pancreatic cancer

Decreased IGF-I levels may correlate with growth defects in newborns with cystic fibrosis

Bristol-Myers Squibb updates pipeline progress for Q3 of 2010

Ipsen Pharma identifies new imidazolidine-2,4-dione derivatives for prostate cancer

Banyu Pharma presents new peptide P518 receptor antagonists

Lumixex launches diagnostic xTAG CYP2D6 Kit in U.S.

Circassia's Toleromune House Dust Mite vaccine shows promise in phase II trial

Genzyme to sell diagnostics business to Sekisui Chemical

Astex Therapeutics claims new fibroblast growth factor receptor inhibitors

Errant Gene Therapeutics receives U.S. federal grant for Thalagen research

Advanced Life Sciences applies for FDA orphan drug status for ALS-886 in ARDS

Phytopharm advances phase II smilagenin trial in early-stage Parkinson's disease

New GlyT-1 inhibitors claimed by sanofi-aventis

Phase III APPRAISE-2 trial of apixaban in ACS discontinued

Reolysin to enter phase I trial in pediatric patients with solid tumors

FDA approves Xgeva for SRE prophylaxis in patients with bone metastases from solid tumors

Second interim RESTORE-CLI data analysis shows primary endpoints met

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...